Zydus Lifesciences stock
ZYDUSLIFE.NSNSEZydus Lifesciences Limited, HealthcareISIN INE010B01027
69Score 69 out of 100, Neutral
Price and trend
84 / 100
Price history
+27% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 3.2% below its 52-week high. Largest decline in 20 years: 61% (June 2017 to August 2019).
Chart figures for advanced users
- SMA 50$12.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.13
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.15
- The lowest closing price of the last twelve months.
- Resistance$13.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Zydus Lifesciences Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $12.79B, is number 21 of 77 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $2.89B (up 16.8% year on year) and earnings of $535.69M (up 11.4%).
- For fiscal 2027, analysts expect on average revenue of $3.42B (up 18.4%) and adjusted earnings per share of $0.42 (down 16%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 158 of 702 in Healthcare, median 53.
- The P/E is 28.8 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 21.2).
- Our model puts fair value at $12.06, with the price 6% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 18.4% a year since 2021.Growth 61
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 61
- Analysts expect strong earnings growthUp 16.3% a year through 2029 (estimates from 23 analysts).Growth 61
Weaknesses
- Negative free cash flowFree cash flow −$127.82M over the last 12 months.Fundamentals 61
- Margin fallingOperating margin 21.3%, average of the prior years 36.2% (to 2025).
Its standout strengths are technical analysis and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $10.05 and expensive above $15.08 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $9.64 (cash-flow model) and $14.49 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 12.7%. At 13.7% the fair value would be $11.28, at 11.7% it would be $13.19.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 24% on the twelve months before. Revenue has grown strongly since 2007, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 52%, operating 21%, net 19%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 14 Feb 2027in 93 days
- Last reported
- 4 Nov 2026EPS reported $0.09 (expected $0.09)below expectations
Analyst estimates
Earnings estimates have barely changed since 22 Oct 2026.
- Earnings per share
- $0.42−1.3%
- Revenue
- $3.42B+1.1%
- Earnings per share
- $0.53+0.3%
- Revenue
- $3.82B+2.0%
MEQIRI has stored the estimates since 22 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Zydus Lifesciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- IpsenIPN.PA $15.31B75
- Yunnan Baiyao Group000538.SZ $14.63B67
- Laurus LabsLAURUSLABS.NS $13.78B70
- Elanco Animal HealthELAN $13.25B48
- Dr. Reddy's LaboratoriesRDY $12.28B62
- CiplaCIPLA.NS $12.09B67
- Zhejiang NHU002001.SZ $11.75B75
- Mankind PharmaMANKIND.NS $11.58B65
ETFs that hold Zydus Lifesciences
Held by 19 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.16% | 0.65% | €4.98B |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.06% | 0.25% | €661.06M |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.03% | 0.17% | €5.24B |
Show 5 more
| iShares MSCI EM Asia UCITS ETFCEBL | 0.03% | 0.20% | €7.14B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.03% | 0.18% | €37.98B |
| iShares MSCI EM UCITS ETF USD (Acc)EUNM | 0.02% | 0.18% | €9.24B |
| Amundi Core MSCI Emerging Markets UCITS ETF EUR DistAEMD | 0.02% | 0.18% | €9.52B |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.02% | 0.18% | €5.26B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.